Semax

Summary

Semax is a synthetic heptapeptide analogue of ACTH(4-10) studied as a neuroactive/nootropic agent, reported to enhance brain-derived neurotrophic factor pathways relevant to neuroplasticity ^[2]. In preclinical rodent models it improved functional recovery after spinal cord injury by targeting the mu-opioid receptor and reducing oxidative stress and neuroinflammation ^[1], and it reduced anxiety-like behaviour, improved learning, and normalized brain biogenic amines after early-life drug exposure in rats ^[3]. In-vitro membrane models also suggest Semax can inhibit copper-induced amyloid-beta aggregation, consistent with proposed neuroprotective properties ^[4]. The available evidence is entirely preclinical and mechanistic; the orthopaedic review explicitly notes a current lack of clinical trials ^[2], so therapeutic benefit in humans remains unproven.

Sources

1. 1. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice British journal of pharmacology, 2025.
2. 2. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
3. 3. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats Neuropeptides, 2021.
4. 4. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models ACS chemical neuroscience, 2022.

For educational purposes only.